Parallel Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Parallel Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40K	Buy	124 +120	+3,000%	+$37.1K	﹤0.01%	2122
2025 Q4	$1.18K	Buy	+4	New	+$745	﹤0.01%	3257
2025 Q1	–	Sell	-2	Closed	-$154	–	3631
2024 Q4	$154	Buy	+2	New	+$145	﹤0.01%	3409
2022 Q4	–	Sell	-25	Closed	-$1K	–	3491
2022 Q3	$1K	Buy	+25	New	+$1.25K	﹤0.01%	2994
2022 Q1	–	Sell	-5	Closed	-$1K	–	3209
2021 Q4	$1K	Sell	5 -6	-55%	-$1.76K	﹤0.01%	2937
2021 Q3	$3K	Buy	11 +8	+267%	+$2.17K	﹤0.01%	2585
2021 Q2	$1K	Buy	+3	New	+$1.07K	﹤0.01%	2801

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Parallel Advisors's PRAX Position: Q1 2026 in Review

Parallel Advisors increased its Praxis Precision Medicines (PRAX) stake by 3,000% in Q1 2026, buying an estimated $37.1K and bringing the position to 124 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #2122.

Parallel Advisors first reported a position in PRAX in Q2 2021 and has held it in 7 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

Parallel Advisors held 124 shares of Praxis Precision Medicines worth $40K as of Q1 2026.
Parallel Advisors bought 120 Praxis Precision Medicines shares in Q1 2026, an estimated $37.1K.
Praxis Precision Medicines made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2122 holding.
Parallel Advisors first reported a position in Praxis Precision Medicines in Q2 2021 and has held it in 7 quarters since.
289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.